IP Library Granted Patent US 9,186,375
Granted Patent B2
US 9,186,375 · App. 13/545,327 · Granted Nov 17, 2015

Glycosaminoglycan compositions in combination with stem cells

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,186,375
App. No.
13/545,327
Granted
Nov 17, 2015
Kind
B2
Abstract

A pharmaceutical preparation for treating connective tissue damage in man and in animals, comprising a therapeutically effective amount of a glycosaminoglycan composition comprising chondroitin sulfate, N-acetyl D-glucosamine, and hyaluronan, in combination with isolated stem cells. Methods of use and kits containing the glycosaminoglycan composition and materials for isolating stem cells and for treating connective tissue damage and repair of cartilage in man and in animals are also provided.

Claims (13)

1. A composition comprising: a glycosaminoglycan composition comprising chondroitin sulfate, N-acetyl D-glucosamine, and hyaluronan; and stem cells, wherein the composition is provided in a container.

2. The composition of claim 1 , wherein said chondroitin sulfate is a mixture of chondroitin 4-sulfate and chondroitin 6-sulfate.

3. The composition of claim 1 , wherein said glycosaminoglycan composition consists essentially of chondroitin sulfate, N-acetyl D-glucosamine, and hyaluronan.

4. The composition of claim 1 , adapted for parenteral administration.

5. The composition of claim 1 , dispersed onto or within a semi-solid or solid material adapted for implantation onto damaged tissues.

6. The composition of claim 1 , further comprising one or more therapeutic agents selected from the group consisting of a synthetic or a non-synthetic corticosteroid agent, nonsteroidal anti-inflammatory agent, antirheumatic agent, immunoregulation agent, immunosuppressant agent, articular function augmentor agent, growth factor, and interleukin production inhibitors.

7. The composition of claim 1 , wherein said glycosaminoglycan composition comprises chondroitin sulfate in a concentration of about 50-100 mg/ml.

8. The composition of claim 7 , wherein said glycosaminoglycan composition comprises chondroitin sulfate in a concentration of about 100 mg/ml.

9. The composition of claim 7 , wherein chondroitin sulfate is chondroitin 4-sulfate, chondroitin 6-sulfate, or a mixture thereof.

10. The composition of claim 1 , wherein said glycosaminoglycan composition comprises N-acetyl D-glucosamine in a concentration of about 50-100 mg/ml.

11. The composition of claim 10 , wherein said glycosaminoglycan composition comprises N-acetyl D-glucosamine in a concentration of about 100 mg/ml.

12. The composition of claim 1 , wherein said glycosaminoglycan composition comprises hyaluronan in a concentration of about 1-5 mg/ml.

13. The composition of claim 12 , wherein said glycosaminoglycan composition comprises hyaluronan in a concentration of about 5 mg/ml.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 5, 2017
From: ARTHRODYNAMIC TECHNOLOGIES, ANIMAL HEALTH DIVISION, INC.
To: ARTHRODYNAMIC HOLDINGS, LLC
Reel/Frame 040854/0031 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 6, 2015
From: MARCUM, FRANK D.; CONWAY, JAMES
To: ARTHRODYNAMIC TECHNOLOGIES, ANIMAL HEALTH DIVISION, INC.
Reel/Frame 036733/0741 →